BioMarin Pharmaceutical Inc. pulled Roctavian from the market. Sales of the hemophilia gene therapy fell drastically short of projections.
The $197 million round is the largest venture capital financing by a Philadelphia-area life sciences company this year.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results